Table 2.

Overview of AEs (Safety-Evaluable Population)

	Placebo (N = 47)	Vicasinabin 30 mg (N = 48)	Vicasinabin 200 mg (N = 43)	All Participants (N = 139)
Total number of AEs	102	110	97	309
Total number of participants with at ≥1:
AE	34 (72.3%)	31 (64.6%)	35 (81.4%)	100 (72.5%)
AE with fatal outcome	1 (2.1%)	0	0	1 (0.7%)
Serious AE	8 (17.0%)	3 (6.3%)	5 (11.6%)	16 (11.6%)
Related serious AE	0	0	0	0
Serious ocular AE	1 (2.1%)	2 (4.2%)	1 (2.3%)	4 (2.9%)
Serious systemic AE	7 (14.9%)	1 (2.1%)	4 (9.3%)	12 (8.7%)
Serious AE leading to withdrawal from treatment	3 (6.4%)	0	0	3 (2.2%)

AE = adverse event.